Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a US-based speciality pharmaceutical company, announced on Monday that has signed a national co-promotion agreement with Verity Pharmaceuticals International Ltd, a Canada-based speciality pharmaceutical company, to support Cumberland's new Sancuso oncology support product.

According to a co-promotion partnership, Verity is to feature Sancuso across the United States via its established oncology commercial organisation and customer network.

Sancuso, the first and only FDA-approved prescription patch, is intended for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment.

Under the terms of the contract, Verity Pharmaceuticals is to promote Sancuso throughout most of the country via its national oncology sales organisation. Both firms will share in the incremental contribution margin resulting from Verity Pharmaceuticals' efforts.